Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II imaging study of 89Zr-trastuzumab PET/CT and early FDG-PET/CT with T-DM1 in advanced HER2-positive breast cancer
NL-OMON43903Phase 2Active, not recruiting
- Sponsor
- Institut Jules Bordet
- Start
- Aug 2012
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab emtansine in breast cancer, sponsored by Institut Jules Bordet. Started Aug 2012; status: active, not recruiting.
02
Drugs
trastuzumab emtansine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON43903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43903.